spacer
home > pmps > winter 2018 > demonstrating bioequivalence
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Demonstrating Bioequivalence

The global generic drugs market has experienced rapid growth in recent years, driving the need to address the specific scientific challenges facing the development of generic drug products. The demand for safe, cost-effective, and effectual treatments of respiratory diseases is also growing due to the rising global prevalence of conditions such as chronic obstructive pulmonary disease and asthma.

The development of generics requires the demonstration of bioequivalence (BE) with a reference product. BE studies typically follow on from the characterisation of a reference product and the design of a pharmaceutically equivalent and bioequivalent product. Demonstrating BE in locally-acting drugs, such as orally inhaled products (OIPs), is particularly challenging, primarily because OIP behaviour is a function of the interactions between the patient, device, and formulation. Advances in bioequivalence methodology provide an opportunity to accelerate the development and marketing of generic drugs while also maintaining safety, quality, and efficacy standards.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Copley graduated from the University of Bath, UK, in 2000 with a master’s degree in aerospace engineering. For eight years, he was Technical Sales Manager and Product Specialist for Copley Scientific’s range of inhaler testing equipment and is now the director of the company. Mark is considered a leading authority in testing methods and systems for metered-dose inhalers, dry powder inhalers, nebulisers, and nasal sprays – authoring and contributing to more than 40 published articles. He also provides application support and consultancy, runs focused training workshops for the inhaled drug testing sector of the pharma industry, and sits on the editorial advisory panel of Inhalation Magazine. An invited member of the European Pharmaceutical Aerosol Group impactor sub-team, Mark has also made recommendations to the Inhalanda working group, leading to subsequent revisions to Ph Eur and USP monographs.

Anna Sipitanou received a BSc in chemistry from the University of Bradford, UK, in 2014, and an MSc in drug discovery and pharmaceutical sciences from the University of Nottingham, UK, in 2015. She also undertook the role of Research Associate at Nottingham, working to build in silico models for the prediction of drug-induced liver injury. Building on her previous experience at Cellomatics Biosciences, Anna joined Copley Scientific in July 2017 as Business Development Manager, playing a key role in the company’s service to customers, including training of a wide range of instruments.
spacer
Mark Copley
spacer
spacer
spacer
Anna Sipitanou
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Countdown to the UK’s leading production line event begins

In light of Nick Peters’, author of the Annual Manufacturing report 2018, comment that “UK manufacturing has come a long way in recent years, as we have seen from their stellar performance in 2017,” it’s no surprise that the PPMA Show is gearing up for its biggest show to date when it returns to the NEC, Birmingham, between 25-27 September 2018.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

11th Annual Proteins & Antibodies Congress

16-17 April 2018, Novotel London West Hotel, Hammersmith, London

Oxford Global Conferences are proud to present our esteemed 11thAnnual Proteins & Antibodies Congress 2018, 16th – 17th April 2018, London, UK. Over 450 proteins, antibodies, peptides and biosimilars & biobetters attendees representing global pharmaceutical organizations, leading biotech companies and internationally renowned academic institutions.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement